Technology thesis · Biotechnology & Health
high conviction matureGene sequencing
Illumina's sequencing monopoly is finally cracking: Roche's SBX re-entry, Ultima's sub-$100 genome and Element AVITI turn 2026-28 into a real price-and-chemistry war, not a one-platform market.
Position maintained continuously · last reviewed Jun 24, 2026
The thesis
State of the art (2026)
Illumina still ships the workhorse short-read fleet (NovaSeq X, list-price $200 genome since 2023) but its monopoly is visibly eroding. The pivotal 2025 event was Roche unveiling SBX, an expanded-molecule nanopore chemistry from its Genia and Stratos acquisitions, putting a diagnostics giant back into instruments. Ultima's wafer-based UG 100, and its 2025 Solaris upgrade, now quotes well under $100 per genome; Element's AVITI and Singular's G4 chip away at the benchtop tier. Long-read leaders PacBio (HiFi) and Oxford Nanopore push into clinical structural-variant work. Population programmes - UK Biobank, All of Us - and oncology buyers like Tempus and Guardant drive volume rather than novel chemistry.
Everything below is live inside CanaryIQ
The full analysis behind the verdict — the structure is real; the content unlocks when you log in.
Signal stack
Evidence stacked leading → lagging
Technology-native KPIs
Metrics that predict trajectory, tracked over time
Landscape map
Who builds what — and who depends on whom
Catalyst calendar
Dated events that will move the position
Technology roadmap
Milestones on the path to maturity
Watchlists
Companies, people and papers — each with a remove-by condition
Decision frameworks
The same call, framed for your desk
Thesis changelog
When our view changed, and why
Change our mind
1 disconfirming conditions
The rest is inside
You've read the verdict. The file is much deeper.
The full signal stack, technology-native KPIs tracked over time, the landscape of who depends on whom, the dated catalyst calendar, decision frameworks for every desk, live watchlists and the changelog of every time our call on Gene sequencing has changed — all live inside CanaryIQ.